Replies to post #13074 on Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

That’s absolutely incorrect. they did not find it reduced the severity. They specifically said the primary endpoint showed no change compared to placebo meaning they failed regarding severity. They said the duration might be less but wouldn’t know without more data which we are only getting from phase 3 because they increased the number of patients in the interim data set to manipulate the numbers and try to find signall. The more promise finding I was happy about was reducing time to ventilation but again, this will only come from phase 3

If they get approval for phase 3